Zenith Epigenetics Proudly Supports Rare Disease Day
ZEN-3694 Expands Development to Include Multiple Rare Oncology Indications
- Calgary, Alberta--(Newsfile Corp. - February 29, 2024) - Zenith Epigenetics Ltd. ("Zenith" or the "Company") announces its support of Rare Disease Day by highlighting our expanded development efforts of BET inhibitor ZEN-3694 for rare oncology diseases.
- Rare Disease Day takes place every year on the last day of February, with this leap year day being the rarest of all Rare Disease Days.
- This event is a global movement to promote equity in healthcare, and access to diagnosis and therapies for individuals living with rare diseases.
- We are very pleased that NUT carcinoma patients receiving ZEN-3694 in clinical trial and compassionate use settings have benefitted from our drug," said Donald McCaffrey, CEO of Zenith Epigenetics.